The last five times the iShares’ Biotechnology ETF (IBB) got this oversold, it subsequently rallied between 18% and 40%, says Miller Tabak’s Matt Maley.
The last five times the iShares’ Biotechnology ETF (IBB) got this oversold, it subsequently rallied between 18% and 40%, says Miller Tabak’s Matt Maley.